Trial · NCT00089141

Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)

NCT00089141, Phase 3, Terminated, Martin, Paul; results first posted 2009-08-26

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD). Trials, record NCT00089141. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00089141

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)
NCT number: NCT00089141
Status: Terminated
Phases: Phase 3
Enrollment: 151 participants, actual
Lead sponsor: Martin, Paul
Conditions: Cancer
Interventions: mycophenolate mofetil, placebo
First posted: 2004-08-05
Last updated: 2013-05-03
Results first posted: 2009-08-26

Source ClinicalTrials.gov

Registered outcomes10

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Cure of Chronic GVHD Without Resorting to Secondary Systemic Therapy	2 years	Withdrawal of all systemic immunosuppressive treatment after resolution of chronic GVHD, before death or onset of recurrent malignancy
Secondary	Definitive Absence of Efficacy Success	2 years	Administration of secondary systemic therapy for chronic GVHD, death during primary therapy, or onset of recurrent malignancy or bronchiolitis obliterans during primary therapy
Secondary	Open Label Systemic Treatment Because of Inadequate Response to Primary Therapy	2 years	Administration of any systemic therapy other than the immunosuppressive agents used for initial treatment, because of persistent or progressive chronic graft-versus-host disease
Secondary	Bronchiolitis Obliterans	within 4 years	Development of bronchiolitis obliterans during treatment
Secondary	Recurrent Malignancy	within 4 years	Development of recurrent malignancy after enrollment in the study
Secondary	Non-relapse Mortality	within 4 years	Death without prior development of recurrent malignancy
Secondary	Death or Recurrent Malignancy	within 4 years	Death due to any cause or development of recurrent malignancy at any time after enrollment
Secondary	Death	within 4 years	Death from any cause after enrollment in the study
Secondary	Withdrawal of Prednisone	within 4 years	Withdrawal of treatment with prednisone after improvement or resolution of chronic GVHD
Secondary	End of Systemic Treatment	within 4 years	Withdrawal of all immunosuppressive treatment without recurrent malignancy

Source ClinicalTrials.gov

Outcomes10

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Cure of Chronic GVHD Without Resorting to Secondary Systemic Therapy	2 years	participants	NUMBER
SECONDARY	Definitive Absence of Efficacy Success	2 years	participants	NUMBER
SECONDARY	Open Label Systemic Treatment Because of Inadequate Response to Primary Therapy	2 years	participants	NUMBER
SECONDARY	Bronchiolitis Obliterans	within 4 years	participants	NUMBER
SECONDARY	Recurrent Malignancy	within 4 years	participants	NUMBER
SECONDARY	Non-relapse Mortality	within 4 years	participants	NUMBER
SECONDARY	Death or Recurrent Malignancy	within 4 years	participants	NUMBER
SECONDARY	Death	within 4 years	participants	NUMBER
SECONDARY	Withdrawal of Prednisone	within 4 years	participants	NUMBER
SECONDARY	End of Systemic Treatment	within 4 years	participants	NUMBER

Source ClinicalTrials.gov

Results by group20

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Cure of Chronic GVHD Without Resorting to Secondary Systemic Therapy	Mycophenolate Mofetil	11	participants
Cure of Chronic GVHD Without Resorting to Secondary Systemic Therapy	Placebo	10	participants
Definitive Absence of Efficacy Success	Mycophenolate Mofetil	45	participants
Definitive Absence of Efficacy Success	Placebo	40	participants
Open Label Systemic Treatment Because of Inadequate Response to Primary Therapy	Mycophenolate Mofetil	24	participants
Open Label Systemic Treatment Because of Inadequate Response to Primary Therapy	Placebo	25	participants
Bronchiolitis Obliterans	Mycophenolate Mofetil	5	participants
Bronchiolitis Obliterans	Placebo	4	participants
Recurrent Malignancy	Mycophenolate Mofetil	17	participants
Recurrent Malignancy	Placebo	10	participants

1 to 10 of 20Source ClinicalTrials.gov

See all 20 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Mycophenolate Mofetil	74
Overall Study	STARTED	Placebo	77
Overall Study	COMPLETED	Mycophenolate Mofetil	56
Overall Study	COMPLETED	Placebo	53
Overall Study	NOT COMPLETED	Mycophenolate Mofetil	18
Overall Study	NOT COMPLETED	Placebo	24

Source ClinicalTrials.gov

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
19270260	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons10

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Mycophenolate Mofetil vs Placebo: Open Label Systemic Treatment Because of Inadequate Response to Primary Therapy	Trial comparisons
Mycophenolate Mofetil vs Placebo: End of Systemic Treatment	Trial comparisons
Mycophenolate Mofetil vs Placebo: Death or Recurrent Malignancy	Trial comparisons
Mycophenolate Mofetil vs Placebo: Definitive Absence of Efficacy Success	Trial comparisons
Mycophenolate Mofetil vs Placebo: Cure of Chronic GVHD Without Resorting to Secondary Systemic Therapy	Trial comparisons
Mycophenolate Mofetil vs Placebo: Withdrawal of Prednisone	Trial comparisons
Mycophenolate Mofetil vs Placebo: Bronchiolitis Obliterans	Trial comparisons
Mycophenolate Mofetil vs Placebo: Recurrent Malignancy	Trial comparisons
Mycophenolate Mofetil vs Placebo: Death	Trial comparisons
Mycophenolate Mofetil vs Placebo: Non-relapse Mortality	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00089141

GET https://conductscience.org/api/trials/v1/NCT00089141/registered

API reference For AI assistants